BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

Core Viewpoint - BioNexus Gene Lab Corp. has filed a registration statement with the SEC to register up to $100 million of securities, aiming to enhance financial flexibility and support growth initiatives in precision diagnostics and gene-based technologies [1][3][4] Group 1: Financial Strategy - The company has entered into an Equity Distribution Agreement with Maxim Group LLC, allowing it to offer and sell up to $20 million of its common stock through an at-the-market (ATM) program [2] - The shelf registration and ATM facility are expected to provide structural capital readiness to support the execution of growth and operating initiatives [4] Group 2: Growth Initiatives - BioNexus is focusing on expanding its footprint in precision oncology, regenerative medicine, and contract biologics manufacturing through its subsidiaries MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. [3][6] - Recent partnerships with Fidelion Diagnostics Pte Ltd. and BirchBioMed Inc. are part of the company's strategy to drive growth [3] Group 3: Market Positioning - The company aims to transform into a next-generation biotechnology platform serving both Asian and U.S. markets [4] - BioNexus is building a platform that spans precision medicine, biologics manufacturing, and AI-integrated healthcare solutions [6]